James H. Stanker - Jan 1, 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Jan 1, 2024
Transactions value $
-$1,445
Form type
4
Date filed
4/12/2024, 04:57 PM
Previous filing
Oct 12, 2023
Next filing
Aug 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Options Exercise +1.68K +33.75% 6.64K Jan 1, 2024 Direct F1, F2
transaction PCSA Common Stock Tax liability -$1.45K -518 -7.8% $2.79 6.12K Jan 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Options Exercise $0 -1.68K -6.51% $0.00 24K Jan 1, 2024 Common Stock 1.68K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distribution of vested restricted shares.
F2 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.